Concepts (217)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Hepacivirus | 7 | 2019 | 1509 | 0.72 | Why? |
| Genotyping Techniques | 1 | 2017 | 360 | 0.55 | Why? |
| Drug Resistance, Viral | 2 | 2019 | 1083 | 0.53 | Why? |
| Reverse Transcription | 1 | 2017 | 673 | 0.52 | Why? |
| Hepatitis C, Chronic | 6 | 2018 | 973 | 0.47 | Why? |
| CD8-Positive T-Lymphocytes | 10 | 2019 | 5837 | 0.41 | Why? |
| Lymphocytic choriomeningitis virus | 3 | 2019 | 98 | 0.40 | Why? |
| Hepatitis Delta Virus | 2 | 2019 | 54 | 0.37 | Why? |
| HLA-B Antigens | 2 | 2019 | 166 | 0.34 | Why? |
| Killer Cells, Natural | 3 | 2019 | 2093 | 0.28 | Why? |
| Epitopes, T-Lymphocyte | 4 | 2019 | 2262 | 0.25 | Why? |
| Lymphocytic Choriomeningitis | 2 | 2019 | 43 | 0.24 | Why? |
| Cytomegalovirus Infections | 2 | 2019 | 667 | 0.23 | Why? |
| Hepatitis B, Chronic | 2 | 2019 | 616 | 0.23 | Why? |
| Genome, Viral | 3 | 2020 | 13157 | 0.22 | Why? |
| Genotype | 3 | 2018 | 4697 | 0.22 | Why? |
| Hepatitis B virus | 2 | 2019 | 882 | 0.22 | Why? |
| Receptors, KIR2DL2 | 1 | 2019 | 4 | 0.21 | Why? |
| Receptors, KIR2DL1 | 1 | 2019 | 23 | 0.21 | Why? |
| Severe Combined Immunodeficiency | 1 | 2021 | 107 | 0.20 | Why? |
| Hepatitis D, Chronic | 1 | 2019 | 16 | 0.20 | Why? |
| Hepatitis delta Antigens | 1 | 2018 | 6 | 0.19 | Why? |
| Aminopeptidases | 1 | 2019 | 41 | 0.19 | Why? |
| Minor Histocompatibility Antigens | 1 | 2019 | 56 | 0.19 | Why? |
| Immunologic Surveillance | 1 | 2019 | 69 | 0.19 | Why? |
| Hepatitis C | 3 | 2019 | 1514 | 0.18 | Why? |
| Hepatitis D | 1 | 2018 | 48 | 0.18 | Why? |
| Torque teno virus | 1 | 2018 | 73 | 0.18 | Why? |
| DNA Virus Infections | 1 | 2018 | 88 | 0.17 | Why? |
| Transfusion Reaction | 1 | 2020 | 245 | 0.17 | Why? |
| Cytotoxicity, Immunologic | 1 | 2019 | 287 | 0.17 | Why? |
| HIV Integrase Inhibitors | 1 | 2019 | 173 | 0.17 | Why? |
| Carcinoembryonic Antigen | 1 | 2018 | 140 | 0.17 | Why? |
| Trans-Activators | 1 | 2018 | 170 | 0.17 | Why? |
| Lipoproteins | 1 | 2018 | 240 | 0.17 | Why? |
| HLA-A Antigens | 1 | 2019 | 196 | 0.17 | Why? |
| BK Virus | 1 | 2018 | 135 | 0.17 | Why? |
| Polyomavirus Infections | 1 | 2018 | 156 | 0.16 | Why? |
| Heterocyclic Compounds, 3-Ring | 1 | 2019 | 275 | 0.16 | Why? |
| Cytomegalovirus | 2 | 2019 | 600 | 0.15 | Why? |
| Sofosbuvir | 2 | 2017 | 518 | 0.15 | Why? |
| Radiation Dosage | 1 | 2020 | 585 | 0.15 | Why? |
| Liver Failure, Acute | 1 | 2019 | 279 | 0.15 | Why? |
| Carrier Proteins | 1 | 2018 | 513 | 0.15 | Why? |
| Cell Adhesion Molecules | 1 | 2018 | 472 | 0.14 | Why? |
| Polymorphism, Genetic | 2 | 2019 | 1074 | 0.14 | Why? |
| DNA, Complementary | 1 | 2017 | 568 | 0.14 | Why? |
| Blood Safety | 1 | 2020 | 459 | 0.14 | Why? |
| Treatment Failure | 2 | 2019 | 2106 | 0.14 | Why? |
| Neurons | 1 | 2020 | 864 | 0.13 | Why? |
| Superinfection | 1 | 2019 | 459 | 0.13 | Why? |
| Lymphocyte Activation | 3 | 2019 | 2742 | 0.13 | Why? |
| Programmed Cell Death 1 Receptor | 1 | 2018 | 724 | 0.13 | Why? |
| HLA-B27 Antigen | 1 | 2013 | 48 | 0.13 | Why? |
| Donor Selection | 1 | 2020 | 804 | 0.13 | Why? |
| Virus Activation | 1 | 2018 | 480 | 0.12 | Why? |
| Histocompatibility Antigens Class I | 1 | 2017 | 624 | 0.12 | Why? |
| Antigens, CD | 1 | 2018 | 984 | 0.12 | Why? |
| Mutation, Missense | 1 | 2017 | 863 | 0.11 | Why? |
| Transcription, Genetic | 1 | 2017 | 1326 | 0.11 | Why? |
| Hepatitis B | 1 | 2019 | 888 | 0.10 | Why? |
| Viremia | 1 | 2018 | 1020 | 0.10 | Why? |
| Real-Time Polymerase Chain Reaction | 2 | 2020 | 11367 | 0.10 | Why? |
| Whole Genome Sequencing | 1 | 2020 | 3239 | 0.09 | Why? |
| Antiviral Agents | 5 | 2019 | 41703 | 0.09 | Why? |
| Germany | 5 | 2021 | 9196 | 0.09 | Why? |
| Viral Nonstructural Proteins | 2 | 2017 | 4810 | 0.08 | Why? |
| Respiratory System | 1 | 2020 | 3213 | 0.08 | Why? |
| Mutation | 4 | 2019 | 12376 | 0.08 | Why? |
| Pharmaceutical Preparations | 1 | 2021 | 1897 | 0.08 | Why? |
| Blood Donors | 1 | 2020 | 2956 | 0.08 | Why? |
| Epitopes | 1 | 2018 | 4113 | 0.08 | Why? |
| Polymerase Chain Reaction | 2 | 2021 | 6740 | 0.08 | Why? |
| Immunoassay | 2 | 2021 | 4485 | 0.07 | Why? |
| Sensitivity and Specificity | 4 | 2021 | 22971 | 0.07 | Why? |
| Liver Transplantation | 2 | 2018 | 2864 | 0.07 | Why? |
| Virus Replication | 4 | 2021 | 14331 | 0.07 | Why? |
| T-Lymphocytes | 2 | 2019 | 6670 | 0.07 | Why? |
| HIV-1 | 1 | 2019 | 3365 | 0.07 | Why? |
| Renal Insufficiency, Chronic | 1 | 2018 | 2654 | 0.07 | Why? |
| Hematopoietic Stem Cell Transplantation | 1 | 2018 | 2426 | 0.07 | Why? |
| Mice, Inbred C57BL | 3 | 2019 | 5542 | 0.06 | Why? |
| Radiography, Thoracic | 1 | 2020 | 5486 | 0.06 | Why? |
| Brain | 1 | 2020 | 5133 | 0.06 | Why? |
| Clinical Laboratory Techniques | 2 | 2020 | 23402 | 0.06 | Why? |
| Liver Diseases | 1 | 2018 | 2698 | 0.06 | Why? |
| Specimen Handling | 1 | 2020 | 6190 | 0.06 | Why? |
| Mesylates | 1 | 2021 | 33 | 0.06 | Why? |
| Physicians | 1 | 2021 | 4214 | 0.06 | Why? |
| Acute Disease | 3 | 2019 | 6029 | 0.06 | Why? |
| Asymptomatic Infections | 1 | 2020 | 7218 | 0.05 | Why? |
| Cyclin T | 1 | 2019 | 3 | 0.05 | Why? |
| Cyclin-Dependent Kinase 9 | 1 | 2019 | 5 | 0.05 | Why? |
| Amino Acid Substitution | 2 | 2018 | 1706 | 0.05 | Why? |
| Humans | 28 | 2021 | 930598 | 0.05 | Why? |
| RNA-Directed DNA Polymerase | 1 | 2020 | 170 | 0.05 | Why? |
| tau Proteins | 1 | 2020 | 162 | 0.05 | Why? |
| Lymphocyte Specific Protein Tyrosine Kinase p56(lck) | 1 | 2018 | 3 | 0.05 | Why? |
| Cytosol | 1 | 2018 | 77 | 0.05 | Why? |
| Sustained Virologic Response | 1 | 2021 | 378 | 0.05 | Why? |
| Immunosuppressive Agents | 1 | 2017 | 6331 | 0.05 | Why? |
| Esters | 1 | 2021 | 300 | 0.05 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2020 | 13720 | 0.05 | Why? |
| Chimera | 1 | 2018 | 83 | 0.05 | Why? |
| Mice, Mutant Strains | 1 | 2017 | 42 | 0.05 | Why? |
| Viral Load | 4 | 2021 | 15850 | 0.04 | Why? |
| Suppression, Genetic | 1 | 2017 | 15 | 0.04 | Why? |
| Interferon-gamma | 2 | 2019 | 2711 | 0.04 | Why? |
| Cell Death | 1 | 2020 | 536 | 0.04 | Why? |
| Transduction, Genetic | 1 | 2018 | 273 | 0.04 | Why? |
| Oxazines | 1 | 2019 | 279 | 0.04 | Why? |
| Protein Isoforms | 1 | 2018 | 347 | 0.04 | Why? |
| Mutant Proteins | 1 | 2018 | 328 | 0.04 | Why? |
| Adult | 12 | 2021 | 244371 | 0.04 | Why? |
| Phenotype | 2 | 2018 | 4037 | 0.04 | Why? |
| Adoptive Transfer | 1 | 2018 | 250 | 0.04 | Why? |
| Critical Care | 1 | 2021 | 14081 | 0.04 | Why? |
| Fluorenes | 1 | 2017 | 101 | 0.04 | Why? |
| Replicon | 1 | 2018 | 232 | 0.04 | Why? |
| Sequence Homology | 1 | 2018 | 448 | 0.04 | Why? |
| AIDS-Related Opportunistic Infections | 1 | 2019 | 260 | 0.04 | Why? |
| Guanidines | 1 | 2021 | 499 | 0.04 | Why? |
| Calcineurin Inhibitors | 1 | 2017 | 218 | 0.04 | Why? |
| Female | 14 | 2021 | 380317 | 0.04 | Why? |
| Antibodies, Viral | 4 | 2021 | 51949 | 0.04 | Why? |
| Piperazines | 1 | 2019 | 445 | 0.04 | Why? |
| Aged | 10 | 2021 | 215776 | 0.04 | Why? |
| RNA, Viral | 3 | 2020 | 32276 | 0.04 | Why? |
| Valine | 1 | 2017 | 359 | 0.04 | Why? |
| Blood Component Transfusion | 1 | 2021 | 740 | 0.04 | Why? |
| Everolimus | 1 | 2017 | 215 | 0.04 | Why? |
| Sirolimus | 1 | 2017 | 240 | 0.04 | Why? |
| DNA Primers | 1 | 2020 | 1170 | 0.04 | Why? |
| Middle Aged | 11 | 2021 | 270681 | 0.04 | Why? |
| Pregnancy Complications, Infectious | 1 | 2021 | 11559 | 0.04 | Why? |
| Bone Marrow Transplantation | 1 | 2018 | 343 | 0.04 | Why? |
| Benzimidazoles | 1 | 2017 | 275 | 0.04 | Why? |
| Immunization, Passive | 2 | 2021 | 10067 | 0.04 | Why? |
| Mice | 3 | 2019 | 21357 | 0.03 | Why? |
| Male | 12 | 2021 | 367725 | 0.03 | Why? |
| CD4 Lymphocyte Count | 1 | 2019 | 1517 | 0.03 | Why? |
| Mice, Knockout | 1 | 2019 | 1815 | 0.03 | Why? |
| Carbamates | 1 | 2017 | 485 | 0.03 | Why? |
| Organoids | 1 | 2020 | 840 | 0.03 | Why? |
| Betacoronavirus | 5 | 2020 | 204454 | 0.03 | Why? |
| Immune Tolerance | 1 | 2019 | 608 | 0.03 | Why? |
| Multicenter Studies as Topic | 1 | 2021 | 2437 | 0.03 | Why? |
| Cyclosporine | 1 | 2017 | 449 | 0.03 | Why? |
| Young Adult | 6 | 2021 | 93724 | 0.03 | Why? |
| Pyrrolidines | 1 | 2017 | 558 | 0.03 | Why? |
| Pyridones | 1 | 2019 | 738 | 0.03 | Why? |
| Healthy Volunteers | 1 | 2019 | 1444 | 0.03 | Why? |
| Tomography, X-Ray Computed | 1 | 2020 | 25144 | 0.03 | Why? |
| HIV Infections | 1 | 2019 | 11620 | 0.03 | Why? |
| Alleles | 1 | 2019 | 1557 | 0.03 | Why? |
| Antitubercular Agents | 1 | 2019 | 775 | 0.03 | Why? |
| Cell Line | 2 | 2019 | 12040 | 0.03 | Why? |
| Imidazoles | 1 | 2017 | 631 | 0.03 | Why? |
| Gene Regulatory Networks | 1 | 2017 | 820 | 0.03 | Why? |
| Pneumonia, Viral | 4 | 2020 | 243684 | 0.03 | Why? |
| Transplant Recipients | 2 | 2018 | 4982 | 0.03 | Why? |
| Coronavirus Infections | 4 | 2020 | 253789 | 0.03 | Why? |
| Virus Diseases | 2 | 2019 | 3779 | 0.03 | Why? |
| Mice, Transgenic | 1 | 2018 | 2739 | 0.03 | Why? |
| Plasma | 1 | 2021 | 1809 | 0.03 | Why? |
| Graft Rejection | 1 | 2021 | 1766 | 0.03 | Why? |
| Immunity | 1 | 2021 | 2651 | 0.03 | Why? |
| Cell Line, Tumor | 1 | 2018 | 3608 | 0.02 | Why? |
| Animals | 4 | 2020 | 78931 | 0.02 | Why? |
| Cluster Analysis | 1 | 2017 | 3001 | 0.02 | Why? |
| Flow Cytometry | 1 | 2017 | 2393 | 0.02 | Why? |
| Prevalence | 2 | 2021 | 25773 | 0.02 | Why? |
| Tissue Donors | 1 | 2018 | 1679 | 0.02 | Why? |
| Hospitals, University | 1 | 2020 | 4173 | 0.02 | Why? |
| Macrophages | 1 | 2019 | 2784 | 0.02 | Why? |
| DNA, Viral | 1 | 2018 | 2521 | 0.02 | Why? |
| Neutralization Tests | 1 | 2021 | 6698 | 0.02 | Why? |
| Amino Acid Sequence | 1 | 2018 | 6049 | 0.02 | Why? |
| Multivariate Analysis | 1 | 2017 | 5440 | 0.02 | Why? |
| Cohort Studies | 2 | 2021 | 36005 | 0.02 | Why? |
| Gene Expression Profiling | 1 | 2017 | 3788 | 0.02 | Why? |
| Adolescent | 3 | 2021 | 86841 | 0.02 | Why? |
| HEK293 Cells | 1 | 2019 | 8394 | 0.02 | Why? |
| Adaptive Immunity | 1 | 2017 | 2585 | 0.02 | Why? |
| Time Factors | 2 | 2020 | 31397 | 0.02 | Why? |
| Drug Therapy, Combination | 1 | 2019 | 7268 | 0.02 | Why? |
| Polymorphism, Single Nucleotide | 1 | 2018 | 3607 | 0.02 | Why? |
| Evolution, Molecular | 1 | 2019 | 3691 | 0.02 | Why? |
| Seroepidemiologic Studies | 1 | 2021 | 10017 | 0.02 | Why? |
| Predictive Value of Tests | 1 | 2020 | 9537 | 0.02 | Why? |
| Liver | 1 | 2019 | 4007 | 0.02 | Why? |
| Immunity, Cellular | 1 | 2018 | 3614 | 0.02 | Why? |
| Antibodies, Neutralizing | 2 | 2021 | 25288 | 0.02 | Why? |
| Vero Cells | 1 | 2020 | 14117 | 0.02 | Why? |
| Chronic Disease | 1 | 2018 | 5139 | 0.02 | Why? |
| Genetic Variation | 1 | 2017 | 3919 | 0.02 | Why? |
| Tuberculosis | 1 | 2019 | 2895 | 0.02 | Why? |
| B-Lymphocytes | 1 | 2017 | 4418 | 0.02 | Why? |
| CD4-Positive T-Lymphocytes | 1 | 2017 | 4545 | 0.01 | Why? |
| Enzyme-Linked Immunosorbent Assay | 1 | 2017 | 7868 | 0.01 | Why? |
| Randomized Controlled Trials as Topic | 1 | 2021 | 10649 | 0.01 | Why? |
| Nervous System Diseases | 1 | 2020 | 4092 | 0.01 | Why? |
| Disease Models, Animal | 1 | 2019 | 10998 | 0.01 | Why? |
| Contact Tracing | 1 | 2021 | 8448 | 0.01 | Why? |
| Aged, 80 and over | 2 | 2021 | 88759 | 0.01 | Why? |
| Pandemics | 4 | 2020 | 389249 | 0.01 | Why? |
| Age Factors | 1 | 2021 | 21039 | 0.01 | Why? |
| Postoperative Complications | 1 | 2018 | 5861 | 0.01 | Why? |
| Pregnancy | 1 | 2021 | 23879 | 0.01 | Why? |
| Immunoglobulin G | 1 | 2021 | 21571 | 0.01 | Why? |
| Retrospective Studies | 2 | 2019 | 105322 | 0.01 | Why? |
| Vaccination | 1 | 2021 | 19050 | 0.01 | Why? |
| Prognosis | 1 | 2019 | 32490 | 0.01 | Why? |
| Treatment Outcome | 1 | 2021 | 51732 | 0.01 | Why? |
| Disease Outbreaks | 1 | 2020 | 27595 | 0.01 | Why? |
| Child | 1 | 2021 | 70012 | 0.01 | Why? |
| Spike Glycoprotein, Coronavirus | 1 | 2021 | 37182 | 0.01 | Why? |
Timm's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(217)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(139)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_